[
  {
    "ts": "2025-12-13T01:25:00+00:00",
    "headline": "U.S. FDA approves AKEEGA速 as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*",
    "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA速 (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by prev",
    "url": "https://finance.yahoo.com/news/u-fda-approves-akeega-first-012500052.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e356e26e-8c6f-3fd7-a734-a9ff9dae4901",
      "content": {
        "id": "e356e26e-8c6f-3fd7-a734-a9ff9dae4901",
        "contentType": "STORY",
        "title": "U.S. FDA approves AKEEGA速 as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care*",
        "description": "",
        "summary": "Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for AKEEGA速 (niraparib and abiraterone acetate dual-action tablet) plus prednisone for the treatment of patients with BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1 Patients with BRCA mutations often have more aggressive forms of prostate cancer leading to poor prognosis, representing a significant unmet need not addressed by prev",
        "pubDate": "2025-12-13T01:25:00Z",
        "displayTime": "2025-12-13T01:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721",
          "originalWidth": 400,
          "originalHeight": 38,
          "caption": "Johnson & Johnson (PRNewsfoto/Johnson & Johnson)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GXCxbsFDDz3fFTI03HwuBw--~B/aD0zODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 400,
              "height": 38,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qhQKh0p3toIAfsx9SijYTA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/7666cc68e9666a174bca3f07e3f94721.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-akeega-first-012500052.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-fda-approves-akeega-first-012500052.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]